Non-Recurring Items and One-Time Charges

Introduction

Non-recurring items are the most important category of EBITDA adjustments in investment banking valuation. They represent charges (or occasionally gains) that occurred in the past period but are not expected to repeat under normal business operations. Removing them from reported EBITDA reveals the company's sustainable, repeatable earning power, which is the correct basis for valuation multiples and DCF projections.

The challenge is that "non-recurring" is a judgment call, not an accounting standard. There is no bright-line rule that defines which items qualify. This is why non-recurring adjustments are one of the most debated elements in M&A negotiations and why the quality of earnings report exists to independently validate them.

Restructuring Charges

Restructuring charges include costs associated with facility closures, workforce reductions, lease terminations, and organizational reorganizations. These are the most common and generally most defensible add-backs because they are associated with discrete, identifiable events.

A company that closed two manufacturing plants and reduced headcount by 500 employees incurred real costs (severance, lease termination fees, asset write-offs) that will not repeat once the restructuring is complete. Adding these costs back to EBITDA is appropriate and straightforward.

Restructuring Charge

A non-recurring expense associated with a significant organizational change, such as a facility closure, workforce reduction, or business line exit. Restructuring charges typically include employee severance and benefits, lease termination penalties, asset impairments related to closed facilities, and professional fees for managing the process. Under US GAAP, restructuring charges are reported separately on the income statement (often as a line item below operating income or within operating expenses, depending on the company's presentation). They are among the most commonly accepted EBITDA add-backs because they are associated with specific, identifiable events with clear start and end dates.

The red flag arises when a company takes restructuring charges repeatedly. If management announces a new restructuring program every 18-24 months, these "one-time" costs are effectively a recurring cost of operating the business. In this case, the analyst should include some level of restructuring cost in normalized EBITDA rather than adding back 100% of every charge.

Litigation Settlements and Legal Costs

One-time legal expenses from lawsuits, regulatory fines, or compliance-related matters are typically added back to EBITDA. A $10 million litigation settlement from a resolved patent infringement case is a clear non-recurring item. Similarly, extraordinary legal fees associated with a specific dispute (as opposed to routine legal costs) qualify as add-backs.

However, for companies in litigation-prone industries (pharmaceuticals, financial services, consumer products), some level of legal expense is a cost of doing business. A pharmaceutical company that settles product liability cases every year should not add back 100% of its legal costs; a normalized level of litigation expense should remain in adjusted EBITDA. The analyst can establish this normalized level by examining the company's 5-year average of litigation-related costs and including that average as an ongoing expense, adding back only the portion of the current year's costs that exceeds the normalized level.

In the financial services sector, regulatory fines and compliance costs have become a persistent feature of the business landscape since the 2008 financial crisis. Major banks have paid tens of billions in fines related to mortgage-backed securities, foreign exchange manipulation, and anti-money-laundering violations. While each individual fine may be labeled "non-recurring," the pattern of ongoing regulatory action makes a strong case for including some level of regulatory expense as a normal cost of operating in the sector.

Asset Impairments and Write-Downs

Non-cash charges from writing down the value of goodwill, intangible assets, inventory, or other assets are added back because they do not affect cash flow. An impairment charge reduces the book value of an asset but does not represent a cash outflow in the period it is recorded. The cash outflow occurred when the asset was originally acquired.

Non-Recurring Item

A gain or loss recognized on the income statement that is not expected to repeat in the normal course of business. In investment banking, non-recurring items are added back to (or subtracted from) reported EBITDA to calculate adjusted EBITDA, which reflects the company's sustainable earning power. The determination of whether an item is truly non-recurring requires judgment and is often the subject of negotiation between buyers and sellers in M&A transactions.

Acquisition-Related Transaction Costs

Investment banking fees, legal costs, due diligence expenses, and integration costs directly associated with a completed M&A transaction are classic non-recurring items. These costs are sunk; they were incurred to complete a specific deal and will not repeat (unless the company makes another acquisition, in which case the new deal's costs are a separate event).

For companies pursuing active acquisition strategies (PE-backed roll-up platforms, serial acquirers), the treatment becomes more nuanced. If a company makes 3-5 tuck-in acquisitions annually as a core part of its growth strategy, the associated transaction costs are arguably a recurring cost of the business model. Treating them as non-recurring inflates adjusted EBITDA in a way that may not reflect true economic performance.

Non-Recurring Revenue (Subtract, Not Add)

Non-recurring adjustments are not limited to expenses. One-time revenue gains must also be adjusted, but in the opposite direction (subtracted from reported EBITDA). Examples include:

These items inflate reported EBITDA but will not repeat, so they must be removed to avoid overstating sustainable earnings.

The impact of non-recurring adjustments is amplified by the valuation multiple. If the EV/EBITDA multiple is 12x, every $1 million of legitimate add-backs increases the implied enterprise value by $12 million. This multiplier effect explains why both sellers and buyers scrutinize every adjustment with such intensity.

For a company with $50 million in reported EBITDA and $8 million in proposed add-backs (resulting in $58 million adjusted EBITDA), the adjustment represents 16% of reported EBITDA. At 12x, the add-backs account for $96 million of the $696 million implied enterprise value, nearly 14% of the total deal price. Whether those add-backs are accepted at face value, partially accepted, or rejected can swing the transaction price by tens of millions of dollars.

The $48 million difference between the seller's and the QoE-validated enterprise value is a direct consequence of the $4 million EBITDA adjustment that the QoE process challenged.